Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients

Cancer Immunity

Volumn 13, Issue 1, 2013, Pages

  Mhawech Fauceglia, Paulette ^a   Wang, Dan ^a   Ali, Liaquat ^a   Lele, Shashikant ^a   Huba, Michael A ^b   Liu, Song ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

CD count; Familial ovarian cancer; Patient outcome

Indexed keywords

PARAFFIN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CD163+ T LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD68+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FEMALE; FOXP3+ T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PATHOLOGY; REGULATORY T LYMPHOCYTE; SURVIVAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UNITED STATES; CD COUNT; CYTOLOGY; EPITHELIUM CELL; FAMILIAL OVARIAN CANCER; IMMUNOLOGY; MACROPHAGE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATIENT OUTCOME; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

CD COUNT; FAMILIAL OVARIAN CANCER; PATIENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; EPITHELIAL CELLS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; T-LYMPHOCYTES;

EID: 84872526021     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012; 62: 10-29. (PMID: 22237781)
2. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998: 4: 2433-2437. (PMID: 9796975)
3. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-710. (PMID: 11179017)
4. James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006; 24: 707-715. (PMID: 16446345)
5. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143: 362-379. (PMID: 16144895)
6. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360. (PMID: 15032581)
7. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.
8. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107: 7875-7880. (PMID: 20385810)
9. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213. (PMID: 12529460)
10. Leffers N, Gooden MJM, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;; 58: 449-459. (PMID: 18791714)
11. Stumpf M, Hasenburg A, Reiner MO, Jütting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, Werner M, Lassmann S. Intraepithelial CD8-positive T lymphocytes predict survival for pateints with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 2009; 101: 1513-1521. (PMID: 19861998)
12. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115: 2891-2902. (PMID: 19472394)
13. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systemic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009; 4: e6412. (PMID: 19641607)
14. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol 2008; 109: 215-219. (PMID: 18314181)
15. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871-881. (PMID: 16606666)
16. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900-8905. (PMID: 17875732)
17. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543. (PMID: 16344461)
18. Piver MS, Mettlin CJ, Tsukada Y, Nasca P, Greenwald P, McPhee ME. Familial Ovarian Cancer Registry. Obstet Gynecol 1984; 64: 195-199. (PMID: 6738953)
19. Piver MS, Goldberg JM, Tsukada Y, Mettlin CJ, Jishi MF, Natarajan N. Characteristics of familial ovarian cancer: a report of the first 1,000 families in the Gilda Radner Familial Ovarian Cancer Registry. Eur J Gynaecol Oncol 1996; 17: 169-176. (PMID: 8780913)
20. Piver MS, Tsukada Y, Werness BA, DiCioccio RA, Whittemore AS, Ponder BA. Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 2000; 78: 166-170. (PMID: 10926797)
21. Piver MS. Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 2002; 85: 9-17. (PMID: 11925114)
22. Piver MS, Rose PG, Freedman MF. Change in International Federation of Gynecology and Obstetrics staging. Am J Obstet Gynecol 1988; 158: 678-679. (PMID: 3348332)
23. The International Agency for Research on Cancer. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Tavassoli FA, Devilee P. (Eds.) Lyon: IARC Press-WHO; 2003; 114-115.
24. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19: 7-15. (PMID: 10638449)
25. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80: 700-707. (PMID: 1407898)
26. Tomsová M, Melichar B, Sedláková I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108: 415-420. (PMID: 18037158)
27. Salvi S, Segalla F, Rao S, Arienti F, Sartori M, Bratina G, Caronni E, Anichini A, Clemente C, Parmiani G, Sensi M. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 1995; 55: 3374-3379. (PMID: 7614474)
28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (PMID: 15322536)
29. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008; 181: 5396-5404. (PMID: 18832696)
30. Wahl SM, Swisher J, McCartney-Francis N, Chen W. TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J Leukoc Biol 2004; 76: 15-24. (PMID: 14966194)
31. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004; 53: 64-72. (PMID: 14593498)
32. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117: 366-372. (PMID: 20144842)
33. Dietl J, Engel JB, Wischhusen J. The role of regulatory T cells in ovarian cancer. Int J Gynecol Cancer 2007; 17: 764-770. (PMID: 17309663)
34. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369-377. (PMID: 16305662)
35. Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S, Mori M. Prognostic value of tumor-infiltrating FOXP3+ regulatory cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2009; 34: 173-179. (PMID: 17928188)
36. The R Project. Accessed from: http://www.r-project.org/